{"financebench_id":"financebench_id_00956","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2022_10K","question_type":"domain-relevant","question_reasoning":"Logical reasoning (based on numerical reasoning)","domain_question_num":"dg05","question":"Are JnJ's FY2022 financials that of a high growth company?","answer":"No, JnJ's FY2022 financials are not of a high growth company as sales grew by 1.3% in FY2022.","justification":null,"dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"Results of Operations\nAnalysis of Consolidated Sales\nFor discussion on results of operations and financial condition pertaining to the fiscal years 2021 and 2020 see the Companys Annual Report on Form 10-\nK for the fiscal year ended January 2, 2022, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.\nIn 2022, worldwide sales increased 1.3% to $94.9 billion as compared to an increase of 13.6% in 2021. These sales changes consisted of the following:\nSales increase\/(decrease) due to:\n2022\n2021\nVolume\n6.9 %\n12.9 %\nPrice\n(0.8)\n(0.7)\nCurrency\n(4.8)\n1.4 \nTotal\n1.3 %\n13.6 %","doc_name":"JOHNSON_JOHNSON_2022_10K","evidence_page_num":27,"evidence_text_full_page":"Results of Operations\nAnalysis of Consolidated Sales\nFor discussion on results of operations and financial condition pertaining to the fiscal years 2021 and 2020 see the Companys Annual Report on Form 10-\nK for the fiscal year ended January 2, 2022, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.\nIn 2022, worldwide sales increased 1.3% to $94.9 billion as compared to an increase of 13.6% in 2021. These sales changes consisted of the following:\nSales increase\/(decrease) due to:\n2022\n2021\nVolume\n6.9 %\n12.9 %\nPrice\n(0.8)\n(0.7)\nCurrency\n(4.8)\n1.4 \nTotal\n1.3 %\n13.6 %\nThe net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 0.1% in 2022 and a negative impact of 0.6% in\n2021.\nSales by U.S. companies were $48.6 billion in 2022 and $47.2 billion in 2021. This represents increases of 3.0% in 2022 and 9.3% in 2021. Sales by\ninternational companies were $46.4 billion in 2022 and $46.6 billion in 2021. This represents a decrease of 0.6% in 2022 and an increase of 18.2% in 2021.\nThe five-year compound annual growth rates for worldwide, U.S. and international sales were 4.4%, 4.0% and 4.9%, respectively. The ten-year\ncompound annual growth rates for worldwide, U.S. and international sales were 3.5%, 5.0% and 2.2%, respectively.\nIn 2022, sales by companies in Europe experienced a decline of 0.6% as compared to the prior year, which included operational growth of 11.0% and a\nnegative currency impact of 11.6%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 6.5% as compared to the prior\nyear, which included operational growth of 10.2%, and a negative currency impact of 3.7%. Sales by companies in the Asia-Pacific, Africa region\nexperienced a decline of 2.8% as compared to the prior year, including operational growth of 6.2% and a negative currency impact of 9.0%.\nIn 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0%\nof the total consolidated revenues. In 2021, the Company had three wholesalers distributing products for all three segments that represented approximately\n14.0%, 11.0% and 11.0% of the total consolidated revenues.\nNote: values may have been rounded\n22\n"}]}
{"financebench_id":"financebench_id_00669","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2022_10K","question_type":"domain-relevant","question_reasoning":"Logical reasoning (based on numerical reasoning) OR Numerical reasoning OR Logical reasoning","domain_question_num":"dg16","question":"What drove gross margin change as of FY2022 for JnJ? If gross margin is not a useful metric for a company like this, then please state that and explain why.","answer":"For FY22, JnJ had changes in gross margin due to: One-time COVID-19 vaccine manufacturing exit related costs, Currency impacts in the Pharmaceutical segment, Commodity inflation in the MedTech and Consumer Health segments, partially offset by Supply chain benefits in the Consumer Health segment.","justification":"Gross margin change is equivalent to the increase in cost of products sold as a percent to sales.","dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"Analysis of Consolidated Earnings Before Provision for Taxes on Income\nConsolidated earnings before provision for taxes on income was $21.7 billion and $22.8 billion for the years 2022 and 2021, respectively. As a percent to\nsales, consolidated earnings before provision for taxes on income was 22.9% and 24.3%, in 2022 and 2021, respectively.\n(Dollars in billions. Percentages in chart are as a percent to total sales)\nCost of Products Sold and Selling, Marketing and Administrative Expenses:\n(Dollars in billions. Percentages in chart are as a percent to total sales)\nCost of products sold increased as a percent to sales driven by:\n\nOne-time COVID-19 vaccine manufacturing exit related costs\n\nCurrency impacts in the Pharmaceutical segment\n\nCommodity inflation in the MedTech and Consumer Health segments\npartially offset by\n\nSupply chain benefits in the Consumer Health segment\nThe intangible asset amortization expense included in cost of products sold was $4.3 billion and $4.7 billion for the fiscal years 2022 and 2021,\nrespectively.","doc_name":"JOHNSON_JOHNSON_2022_10K","evidence_page_num":33,"evidence_text_full_page":"Analysis of Consolidated Earnings Before Provision for Taxes on Income\nConsolidated earnings before provision for taxes on income was $21.7 billion and $22.8 billion for the years 2022 and 2021, respectively. As a percent to\nsales, consolidated earnings before provision for taxes on income was 22.9% and 24.3%, in 2022 and 2021, respectively.\n(Dollars in billions. Percentages in chart are as a percent to total sales)\nCost of Products Sold and Selling, Marketing and Administrative Expenses:\n(Dollars in billions. Percentages in chart are as a percent to total sales)\nCost of products sold increased as a percent to sales driven by:\n\nOne-time COVID-19 vaccine manufacturing exit related costs\n\nCurrency impacts in the Pharmaceutical segment\n\nCommodity inflation in the MedTech and Consumer Health segments\npartially offset by\n\nSupply chain benefits in the Consumer Health segment\nThe intangible asset amortization expense included in cost of products sold was $4.3 billion and $4.7 billion for the fiscal years 2022 and 2021,\nrespectively.\n28\n"}]}
{"financebench_id":"financebench_id_00711","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2022_10K","question_type":"domain-relevant","question_reasoning":"Numerical reasoning OR Logical reasoning","domain_question_num":"dg25","question":"Roughly how many times has JnJ sold its inventory in FY2022? Calculate inventory turnover ratio for FY2022; if conventional inventory management is not meaningful for the company then state that and explain why.","answer":"JnJ sold its inventory 2.7 times in FY2022.","justification":"Inventory turnover ratio = Cost of products sold\/average inventories = 31,089\/((12,483+10,387)\/2) = 2.7","dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"JOHNSON & JOHNSON AND SUBSIDIARIES\nCONSOLIDATED BALANCE SHEETS\nAt January 1, 2023 and January 2, 2022\n(Dollars in Millions Except Share and Per Share Amounts) (Note 1)\n2022\n2021\nAssets\nCurrent assets\n \n \nCash and cash equivalents (Notes 1 and 2)\n$\n14,127 \n14,487 \nMarketable securities (Notes 1 and 2)\n9,392 \n17,121 \nAccounts receivable trade, less allowances for doubtful accounts $203 (2021, $230)\n16,160 \n15,283 \nInventories (Notes 1 and 3)\n12,483 \n10,387","doc_name":"JOHNSON_JOHNSON_2022_10K","evidence_page_num":45,"evidence_text_full_page":"JOHNSON & JOHNSON AND SUBSIDIARIES\nCONSOLIDATED BALANCE SHEETS\nAt January 1, 2023 and January 2, 2022\n(Dollars in Millions Except Share and Per Share Amounts) (Note 1)\n2022\n2021\nAssets\nCurrent assets\n \n \nCash and cash equivalents (Notes 1 and 2)\n$\n14,127 \n14,487 \nMarketable securities (Notes 1 and 2)\n9,392 \n17,121 \nAccounts receivable trade, less allowances for doubtful accounts $203 (2021, $230)\n16,160 \n15,283 \nInventories (Notes 1 and 3)\n12,483 \n10,387 \nPrepaid expenses and other receivables\n3,132 \n3,701 \nTotal current assets\n55,294 \n60,979 \nProperty, plant and equipment, net (Notes 1 and 4)\n19,803 \n18,962 \nIntangible assets, net (Notes 1 and 5)\n48,325 \n46,392 \nGoodwill (Notes 1 and 5)\n45,231 \n35,246 \nDeferred taxes on income (Note 8)\n9,123 \n10,223 \nOther assets\n9,602 \n10,216 \nTotal assets\n$\n187,378 \n182,018 \nLiabilities and Shareholders Equity\n \n \nCurrent liabilities\n \n \nLoans and notes payable (Note 7)\n$\n12,771 \n3,766 \nAccounts payable\n11,703 \n11,055 \nAccrued liabilities\n11,456 \n13,612 \nAccrued rebates, returns and promotions\n14,417 \n12,095 \nAccrued compensation and employee related obligations\n3,328 \n3,586 \nAccrued taxes on income (Note 8)\n2,127 \n1,112 \nTotal current liabilities\n55,802 \n45,226 \nLong-term debt (Note 7)\n26,888 \n29,985 \nDeferred taxes on income (Note 8)\n6,374 \n7,487 \nEmployee related obligations (Notes 9 and 10)\n6,767 \n8,898 \nLong-term taxes payable (Note 1)\n4,306 \n5,713 \nOther liabilities\n10,437 \n10,686 \nTotal liabilities\n110,574 \n107,995 \nCommitments and Contingencies (Note 19)\nShareholders equity\n \n \nPreferred stock without par value (authorized and unissued 2,000,000 shares)\n \n \nCommon stock par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued\n3,119,843,000 shares)\n3,120 \n3,120 \nAccumulated other comprehensive income (loss) (Note 13)\n(12,967)\n(13,058)\nRetained earnings\n128,345 \n123,060 \n \n118,498 \n113,122 \nLess: common stock held in treasury, at cost (Note 12) (506,246,000 shares and 490,878,000 shares)\n41,694 \n39,099 \nTotal shareholders equity\n76,804 \n74,023 \nTotal liabilities and shareholders equity\n$\n187,378 \n182,018 \nSee Notes to Consolidated Financial Statements\n40\n"},{"evidence_text":"JOHNSON & JOHNSON AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF EARNINGS\n(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)\n2022\n2021\n2020\nSales to customers\n$\n94,943 \n93,775 \n82,584 \nCost of products sold\n31,089 \n29,855 \n28,427","doc_name":"JOHNSON_JOHNSON_2022_10K","evidence_page_num":46,"evidence_text_full_page":"JOHNSON & JOHNSON AND SUBSIDIARIES\nCONSOLIDATED STATEMENTS OF EARNINGS\n(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)\n2022\n2021\n2020\nSales to customers\n$\n94,943 \n93,775 \n82,584 \nCost of products sold\n31,089 \n29,855 \n28,427 \nGross profit\n63,854 \n63,920 \n54,157 \nSelling, marketing and administrative expenses\n24,765 \n24,659 \n22,084 \nResearch and development expense\n14,603 \n14,714 \n12,159 \nIn-process research and development (Note 5)\n783 \n900 \n181 \nInterest income\n(490)\n(53)\n(111)\nInterest expense, net of portion capitalized (Note 4)\n276 \n183 \n201 \nOther (income) expense, net\n1,871 \n489 \n2,899 \nRestructuring (Note 20)\n321 \n252 \n247 \nEarnings before provision for taxes on income\n21,725 \n22,776 \n16,497 \nProvision for taxes on income (Note 8)\n3,784 \n1,898 \n1,783 \nNet earnings\n$\n17,941 \n20,878 \n14,714 \nNet earnings per share (Notes 1 and 15)\n Basic\n$\n6.83 \n7.93 \n5.59 \n Diluted\n$\n6.73 \n7.81 \n5.51 \nAverage shares outstanding (Notes 1 and 15)\n Basic\n2,625.2 \n2,632.1 \n2,632.8 \n Diluted\n2,663.9 \n2,674.0 \n2,670.7 \nSee Notes to Consolidated Financial Statements\n41\n"}]}
{"financebench_id":"financebench_id_00651","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2022Q4_EARNINGS","question_type":"novel-generated","question_reasoning":null,"domain_question_num":null,"question":"Is growth in JnJ's adjusted EPS expected to accelerate in FY2023?","answer":"No, rate of growth in adjusted EPS is expected to decelerate slightly from 3.6% in FY2022 to 3.5% in FY2023.","justification":"FY2023 adjusted EPS growth of 3.5% is slightly lower than FY2022 adjusted EPS growth of 3.6%.","dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable \nforeign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding \nCOVID-19 Vaccine of 4.6%* \n 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 \nincreasing by 10.3%* \n__________________________________________________________________________________________ \n 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial \nexecution partially offset by unfavorable foreign exchange. Operational growth of 6.1%* \n 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 \nincreasing by 3.6%* \n__________________________________________________________________________________________ \n Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and \nadjusted operational EPS of $10.50, reflecting growth of 3.5%*","doc_name":"JOHNSON_JOHNSON_2022Q4_EARNINGS","evidence_page_num":0,"evidence_text_full_page":" \n \n \n \nFOR IMMEDIATE RELEASE \n \n 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable \nforeign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding \nCOVID-19 Vaccine of 4.6%* \n 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 \nincreasing by 10.3%* \n__________________________________________________________________________________________ \n 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial \nexecution partially offset by unfavorable foreign exchange. Operational growth of 6.1%* \n 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 \nincreasing by 3.6%* \n__________________________________________________________________________________________ \n Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and \nadjusted operational EPS of $10.50, reflecting growth of 3.5%* \nNew Brunswick, N.J. (January 24, 2023) Johnson & Johnson (NYSE: JNJ) today announced results for fourth-\nquarter and full year 2022. Our full year 2022 results reflect the continued strength and stability of our three \nbusiness segments, despite macroeconomic challenges, said Joaquin Duato, Chairman of the Board and Chief \nExecutive Officer. I am inspired by our employees who make a difference in the health and lives of people around \nthe world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, \nwhile also investing strategically to deliver long-term value. \n \nOVERALL FINANCIAL RESULTS \n \n \nQ4 \n \nFull Year \n($ in Millions, except EPS) \n2022 \n2021 \n% Change \n \n2022 \n2021 \n% Change \nReported Sales \n$23,706 \n$24,804 \n(4.4)% \n \n$94,943 \n$93,775 \n1.3% \nNet Earnings \n$3,520 \n$4,736 \n(25.7)% \n \n$17,941 \n$20,878 \n(14.1)% \nEPS (diluted) \n$1.33 \n$1.77 \n(24.9)% \n \n$6.73 \n$7.81 \n(13.8)% \n \n \n \n \n \n \n \n \n"}]}
{"financebench_id":"financebench_id_01484","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2022Q4_EARNINGS","question_type":"novel-generated","question_reasoning":null,"domain_question_num":null,"question":"How did JnJ's US sales growth compare to international sales growth in FY2022?","answer":"US sales increased 3.0% vs international sales decline of 0.6%.","justification":null,"dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"REGIONAL SALES RESULTS \n \nQ4 \n \n% Change \n($ in Millions) \n2022 \n2021 \nReported \nOperational1,2 \nCurrency \nAdjusted \nOperational1,3 \nU.S. \n$12,516 \n$12,163 \n2.9% \n2.9 \n- \n2.7 \nInternational \n11,190 \n12,641 \n(11.5) \n(1.1) \n(10.4) \n(1.0) \nWorldwide \n$23,706 \n$24,804 \n(4.4)% \n0.9 \n(5.3) \n0.8 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nFull Year \n \n% Change \n($ in Millions) \n2022 \n2021 \nReported \nOperational1,2 \nCurrency \nAdjusted \nOperational1,3 \nU.S. \n$48,580 \n$47,156 \n3.0% \n3.0 \n- \n3.0 \nInternational \n46,363 \n46,619 \n(0.6)% \n9.1 \n(9.7) \n9.3 \nWorldwide \n$94,943 \n$93,775 \n1.3% \n6.1 \n(4.8) \n6.2","doc_name":"JOHNSON_JOHNSON_2022Q4_EARNINGS","evidence_page_num":1,"evidence_text_full_page":" \n \nQ4 \n \nFull Year \nNon-GAAP* ($ in Millions, except EPS) \n2022 \n2021 \n% Change \n \n2022 \n2021 \n% Change \nOperational Sales1,2 \n \n \n0.9% \n \n \n \n6.1% \nAdjusted Operational Sales1,3 \n \n \n0.8% \n \n \n \n6.2% \nAdjusted Net Earnings1,4 \n$6,218 \n$5,678 \n9.5% \n \n$27,038 \n$26,195 \n3.2% \nAdjusted EPS (diluted)1,4 \n$2.35 \n$2.13 \n10.3% \n \n$10.15 \n$9.80 \n3.6% \n \n 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules \n 2 Excludes the impact of translational currency \n 3 Excludes the net impact of acquisitions and divestitures and translational currency \n 4 Excludes intangible amortization expense and special items \n Note: values may have been rounded \n \nREGIONAL SALES RESULTS \n \nQ4 \n \n% Change \n($ in Millions) \n2022 \n2021 \nReported \nOperational1,2 \nCurrency \nAdjusted \nOperational1,3 \nU.S. \n$12,516 \n$12,163 \n2.9% \n2.9 \n- \n2.7 \nInternational \n11,190 \n12,641 \n(11.5) \n(1.1) \n(10.4) \n(1.0) \nWorldwide \n$23,706 \n$24,804 \n(4.4)% \n0.9 \n(5.3) \n0.8 \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nFull Year \n \n% Change \n($ in Millions) \n2022 \n2021 \nReported \nOperational1,2 \nCurrency \nAdjusted \nOperational1,3 \nU.S. \n$48,580 \n$47,156 \n3.0% \n3.0 \n- \n3.0 \nInternational \n46,363 \n46,619 \n(0.6)% \n9.1 \n(9.7) \n9.3 \nWorldwide \n$94,943 \n$93,775 \n1.3% \n6.1 \n(4.8) \n6.2 \n \n 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules \n 2 Excludes the impact of translational currency \n 3 Excludes the net impact of acquisitions and divestitures and translational currency \n Note: Values may have been rounded \n \nSEGMENT SALES RESULTS \n \nQ4 \n \n% Change \n($ in Millions) \n2022 \n2021 \nReported \nOperational1,2 \nCurrency \nAdjusted \nOperational1,3 \n \nConsumer Health4 \n$3,767 \n$3,728 \n1.0% \n6.4 \n(5.4) \n6.4 \n \nPharmaceutical4 \n13,163 \n14,217 \n(7.4) \n(2.5) \n(4.9) \n(2.3) \n \nMedTech \n6,776 \n6,859 \n(1.2) \n4.9 \n(6.1) \n4.4 \n \nWorldwide \n$23,706 \n$24,804 \n(4.4)% \n0.9 \n(5.3) \n0.8 \n \n \n \n \n \n \n \n \n \n"}]}
{"financebench_id":"financebench_id_01488","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2023_8K_dated-2023-08-30","question_type":"novel-generated","question_reasoning":null,"domain_question_num":null,"question":"Which business segment of JnJ will be treated as a discontinued operation from August 30, 2023 onward?","answer":"The Consumer Health business segment will be treated as a discontinued operation from August 30, 2023 onward.","justification":null,"dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"Exhibit 99.1\nJohnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue\nSeparation\n\nCompany expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and\nAdjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine\n\nCompany expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of\n12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-\npoint\n\nCompany reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefit\nof approximately 73.5 million shares or $0.28 benefit to EPS\n\nCompany secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering and maintains 9.5%\nof equity stake in Kenvue\n\nCompany maintains its quarterly dividend of $1.19 per share\nNew Brunswick, N.J. (August 30, 2023) Johnson & Johnson (NYSE: JNJ) (the Company) today announced updates to its financials and\n2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. The\nCompany has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidance\nfound in this release, which may be accessed by visiting the Investors section of the Company's website at webcasts & presentations.\nThe completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on delivering\ntransformative healthcare solutions to patients, said Joaquin Duato, Chairman of the Board and Chief Executive Officer. We are incredibly\nproud of the focus and dedication of our employees worldwide to achieve this milestone, which we are confident will unlock near- and long-\nterm value for all of our stakeholders.\nAs previously announced, the Company recently completed an exchange offer to finalize the separation of Kenvue Inc., formerly Johnson &\nJohnsons Consumer Health business. As a result of the completion of the exchange offer, Johnson & Johnson will now present its\nConsumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of\n2023","doc_name":"JOHNSON_JOHNSON_2023_8K_dated-2023-08-30","evidence_page_num":3,"evidence_text_full_page":"Exhibit 99.1\nJohnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue\nSeparation\n\nCompany expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and\nAdjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine\n\nCompany expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of\n12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-\npoint\n\nCompany reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefit\nof approximately 73.5 million shares or $0.28 benefit to EPS\n\nCompany secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering and maintains 9.5%\nof equity stake in Kenvue\n\nCompany maintains its quarterly dividend of $1.19 per share\nNew Brunswick, N.J. (August 30, 2023) Johnson & Johnson (NYSE: JNJ) (the Company) today announced updates to its financials and\n2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. The\nCompany has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidance\nfound in this release, which may be accessed by visiting the Investors section of the Company's website at webcasts & presentations.\nThe completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on delivering\ntransformative healthcare solutions to patients, said Joaquin Duato, Chairman of the Board and Chief Executive Officer. We are incredibly\nproud of the focus and dedication of our employees worldwide to achieve this milestone, which we are confident will unlock near- and long-\nterm value for all of our stakeholders.\nAs previously announced, the Company recently completed an exchange offer to finalize the separation of Kenvue Inc., formerly Johnson &\nJohnsons Consumer Health business. As a result of the completion of the exchange offer, Johnson & Johnson will now present its\nConsumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of\n2023.\n"}]}
{"financebench_id":"financebench_id_01490","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2023_8K_dated-2023-08-30","question_type":"novel-generated","question_reasoning":null,"domain_question_num":null,"question":"What is the amount of the gain accruing to JnJ as a result of the separation of its Consumer Health business segment, as of August 30, 2023?","answer":"JnJ will make a gain of approximately $20 billion from the separation of its Consumer Health business segment.","justification":null,"dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"Exhibit 99.1\nJohnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue\nSeparation\n\nCompany expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and\nAdjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine\n\nCompany expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of\n12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-\npoint\n\nCompany reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefit\nof approximately 73.5 million shares or $0.28 benefit to EPS\n\nCompany secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering and maintains 9.5%\nof equity stake in Kenvue\n\nCompany maintains its quarterly dividend of $1.19 per share\nNew Brunswick, N.J. (August 30, 2023) Johnson & Johnson (NYSE: JNJ) (the Company) today announced updates to its financials and\n2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. The\nCompany has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidance\nfound in this release, which may be accessed by visiting the Investors section of the Company's website at webcasts & presentations.\nThe completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on delivering\ntransformative healthcare solutions to patients, said Joaquin Duato, Chairman of the Board and Chief Executive Officer. We are incredibly\nproud of the focus and dedication of our employees worldwide to achieve this milestone, which we are confident will unlock near- and long-\nterm value for all of our stakeholders.\nAs previously announced, the Company recently completed an exchange offer to finalize the separation of Kenvue Inc., formerly Johnson &\nJohnsons Consumer Health business. As a result of the completion of the exchange offer, Johnson & Johnson will now present its\nConsumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of\n2023.","doc_name":"JOHNSON_JOHNSON_2023_8K_dated-2023-08-30","evidence_page_num":3,"evidence_text_full_page":"Exhibit 99.1\nJohnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue\nSeparation\n\nCompany expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and\nAdjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine\n\nCompany expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of\n12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-\npoint\n\nCompany reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefit\nof approximately 73.5 million shares or $0.28 benefit to EPS\n\nCompany secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering and maintains 9.5%\nof equity stake in Kenvue\n\nCompany maintains its quarterly dividend of $1.19 per share\nNew Brunswick, N.J. (August 30, 2023) Johnson & Johnson (NYSE: JNJ) (the Company) today announced updates to its financials and\n2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. The\nCompany has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidance\nfound in this release, which may be accessed by visiting the Investors section of the Company's website at webcasts & presentations.\nThe completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on delivering\ntransformative healthcare solutions to patients, said Joaquin Duato, Chairman of the Board and Chief Executive Officer. We are incredibly\nproud of the focus and dedication of our employees worldwide to achieve this milestone, which we are confident will unlock near- and long-\nterm value for all of our stakeholders.\nAs previously announced, the Company recently completed an exchange offer to finalize the separation of Kenvue Inc., formerly Johnson &\nJohnsons Consumer Health business. As a result of the completion of the exchange offer, Johnson & Johnson will now present its\nConsumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of\n2023.\n"}]}
{"financebench_id":"financebench_id_01491","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2023_8K_dated-2023-08-30","question_type":"novel-generated","question_reasoning":null,"domain_question_num":null,"question":"What is the amount of the cash proceeds that JnJ realised from the separation of Kenvue (formerly Consumer Health business segment), as of August 30, 2023?","answer":"JnJ realised $13.2 billion in cash proceeds from the separation of Kenvue.","justification":null,"dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"Exhibit 99.1\nJohnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue\nSeparation\n\nCompany expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and\nAdjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine\n\nCompany expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of\n12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-\npoint\n\nCompany reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefit\nof approximately 73.5 million shares or $0.28 benefit to EPS\n\nCompany secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering and maintains 9.5%\nof equity stake in Kenvue\n\nCompany maintains its quarterly dividend of $1.19 per share\nNew Brunswick, N.J. (August 30, 2023) Johnson & Johnson (NYSE: JNJ) (the Company) today announced updates to its financials and\n2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. The\nCompany has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidance\nfound in this release, which may be accessed by visiting the Investors section of the Company's website at webcasts & presentations.\nThe completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on delivering\ntransformative healthcare solutions to patients, said Joaquin Duato, Chairman of the Board and Chief Executive Officer. We are incredibly\nproud of the focus and dedication of our employees worldwide to achieve this milestone, which we are confident will unlock near- and long-\nterm value for all of our stakeholders.\nAs previously announced, the Company recently completed an exchange offer to finalize the separation of Kenvue Inc., formerly Johnson &\nJohnsons Consumer Health business. As a result of the completion of the exchange offer, Johnson & Johnson will now present its\nConsumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of\n2023.","doc_name":"JOHNSON_JOHNSON_2023_8K_dated-2023-08-30","evidence_page_num":3,"evidence_text_full_page":"Exhibit 99.1\nJohnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue\nSeparation\n\nCompany expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and\nAdjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine\n\nCompany expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of\n12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the mid-\npoint\n\nCompany reduced outstanding share count by approximately 191 million; 2023 guidance reflects only a partial-year benefit\nof approximately 73.5 million shares or $0.28 benefit to EPS\n\nCompany secured $13.2 billion in cash proceeds from the Kenvue debt offering and initial public offering and maintains 9.5%\nof equity stake in Kenvue\n\nCompany maintains its quarterly dividend of $1.19 per share\nNew Brunswick, N.J. (August 30, 2023) Johnson & Johnson (NYSE: JNJ) (the Company) today announced updates to its financials and\n2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech. The\nCompany has published a recorded webinar for investors to provide additional context behind the updated financials and 2023 guidance\nfound in this release, which may be accessed by visiting the Investors section of the Company's website at webcasts & presentations.\nThe completion of this transaction uniquely positions Johnson & Johnson as a Pharmaceutical and MedTech company focused on delivering\ntransformative healthcare solutions to patients, said Joaquin Duato, Chairman of the Board and Chief Executive Officer. We are incredibly\nproud of the focus and dedication of our employees worldwide to achieve this milestone, which we are confident will unlock near- and long-\nterm value for all of our stakeholders.\nAs previously announced, the Company recently completed an exchange offer to finalize the separation of Kenvue Inc., formerly Johnson &\nJohnsons Consumer Health business. As a result of the completion of the exchange offer, Johnson & Johnson will now present its\nConsumer Health business financial results as discontinued operations, including a gain of approximately $20 billion in the third quarter of\n2023.\n"}]}
{"financebench_id":"financebench_id_01487","company":"Johnson & Johnson","doc_name":"JOHNSON_JOHNSON_2023Q2_EARNINGS","question_type":"novel-generated","question_reasoning":null,"domain_question_num":null,"question":"Did JnJ's net earnings as a percent of sales increase in Q2 of FY2023 compared to Q2 of FY2022?","answer":"Yes, net earnings as a percent of sales increased from 20% in Q2 of FY2022 to 20.1% in Q2 of FY2023.","justification":null,"dataset_subset_label":"OPEN_SOURCE","evidence":[{"evidence_text":"Johnson & Johnson and Subsidiaries\n \nCondensed Consolidated Statement of Earnings \n \n(Unaudited; in Millions Except Per Share Figures)\nPercent\nPercent\nPercent\nIncrease\nAmount\nto Sales\nAmount\nto Sales\n(Decrease)\nSales to customers\n25,530\n$ \n 100.0\n24,020\n$ \n 100.0\n6.3\nCost of products sold\n 8,212\n32.2\n \n7,919\n \n33.0\n \n3.7\nGross Profit\n17,318\n \n67.8\n \n16,101\n \n67.0\n \n7.6\nSelling, marketing and administrative expenses\n 6,665\n26.1\n \n6,226\n \n25.9\n \n7.1\nResearch and development expense\n 3,829\n15.0\n \n3,703\n \n15.4\n \n3.4\nInterest (income) expense, net\n(23)\n \n (0.1)\n(26)\n \n (0.1)\n \nOther (income) expense, net*\n(60)\n \n (0.2)\n273\n \n1.1\n \n \nRestructuring\n 145\n0.5\n \n85\n \n0.4\n \n \nEarnings before provision for taxes on income\n 6,762\n26.5\n \n5,840\n \n24.3\n \n15.8\nProvision for taxes on income\n 1,618\n6.4\n \n1,026\n \n4.3\n \n57.7\nNet earnings\n5,144\n$ \n20.1\n \n4,814\n$ \n20.0\n \n6.9","doc_name":"JOHNSON_JOHNSON_2023Q2_EARNINGS","evidence_page_num":9,"evidence_text_full_page":"Johnson & Johnson and Subsidiaries\n \nCondensed Consolidated Statement of Earnings \n \n(Unaudited; in Millions Except Per Share Figures)\nPercent\nPercent\nPercent\nIncrease\nAmount\nto Sales\nAmount\nto Sales\n(Decrease)\nSales to customers\n25,530\n$ \n 100.0\n24,020\n$ \n 100.0\n6.3\nCost of products sold\n 8,212\n32.2\n \n7,919\n \n33.0\n \n3.7\nGross Profit\n17,318\n \n67.8\n \n16,101\n \n67.0\n \n7.6\nSelling, marketing and administrative expenses\n 6,665\n26.1\n \n6,226\n \n25.9\n \n7.1\nResearch and development expense\n 3,829\n15.0\n \n3,703\n \n15.4\n \n3.4\nInterest (income) expense, net\n(23)\n \n (0.1)\n(26)\n \n (0.1)\n \nOther (income) expense, net*\n(60)\n \n (0.2)\n273\n \n1.1\n \n \nRestructuring\n 145\n0.5\n \n85\n \n0.4\n \n \nEarnings before provision for taxes on income\n 6,762\n26.5\n \n5,840\n \n24.3\n \n15.8\nProvision for taxes on income\n 1,618\n6.4\n \n1,026\n \n4.3\n \n57.7\nNet earnings\n5,144\n$ \n20.1\n \n4,814\n$ \n20.0\n \n6.9\nNet earnings per share (Diluted)\n$ 1.96\n1.80\n$ \n8.9\nAverage shares outstanding (Diluted)\n2,625.7\n2,667.9\nEffective tax rate\n23.9 %\n17.6 %\nAdjusted earnings before provision for taxes and net earnings (1)\nEarnings before provision for taxes on income\n8,824\n$ \n34.6\n8,171\n$ \n34.0\n8.0\nNet earnings \n7,358\n$ \n28.8\n6,912\n$ \n28.8\n6.5\nNet earnings per share (Diluted)\n$ 2.80\n2.59\n$ \n8.1\nEffective tax rate\n16.6 %\n15.4 %\n(1) See Reconciliation of Non-GAAP Financial Measures.\nSECOND QUARTER\n2023\n2022\n* Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public \noffering on May 8, 2023 through the end of the fiscal second quarter. \n"}]}
